A synthetic peptide derived from a fragment of ACTH, developed in Russia and studied around BDNF expression, offered on Promise today only inside the Semax / Selank combination.
Coming soon
You are on the list. We will email you if Semax becomes available — and nothing else. Joining is not a medical request, and no prescription has been issued.
That did not go through. Check the address and try again.
Semax on its own is not available yet; the waitlist tells us to prioritize it, and any future prescription would come from a licensed provider.
How it works once Semax is available
Every treatment gets its own online clinical questionnaire — your history, medications, and goals.
A clinician reads your history and takes the time to get it right before anything is prescribed.
Compounded for your prescription and shipped cold-chain, with care-team check-ins after.
Semax is easy to find online and hard to trust there. Promise works the way medicine is supposed to work — a clinician decides, a licensed pharmacy fills, and someone stays accountable to you.
Prescribed for you specifically, after a real look at your health history — never pulled off a shelf.
Your prescription is compounded for you by a licensed U.S. pharmacy — not a mystery vial from an unregulated website.
Temperature-safe shipping, follow-up check-ins, and a care team that answers — before and after your medication arrives.
Semax is built from a short stretch of adrenocorticotropic hormone with a stabilizing tail added. The fragment it derives from carries none of the parent hormone's cortisol-releasing activity.
Research interest centers on brain-derived neurotrophic factor expression and on neuromodulatory pathways. That is a mechanism under study, not a described outcome in a person.
Standalone Semax cannot be prescribed through Promise today. If it ever is, a licensed provider decides after reading your history.
Semax is not available on its own through Promise. It reaches patients here one way only, inside the Semax / Selank combination, where both peptides are compounded into a single preparation. This page describes the standalone, which we do not yet offer.
There is no intake questionnaire for it, no price, and no date. What follows is what the compound is and what is actually known about it.
Semax is a synthetic peptide built from a short stretch of adrenocorticotropic hormone, with a small proline-glycine-proline tail added to the end of the chain. That tail is the practical part of the design — it slows enzymatic breakdown enough for the molecule to be studied, and it is the same trick used to stabilize several peptides of this generation.
The fragment Semax derives from is not the part of ACTH that drives cortisol release. This matters, and it is often garbled in secondhand accounts: Semax is derived from a hormone but does not act as one. It belongs in our brain health and memory category because of where the research points, not because of anything hormonal.
Most of the mechanistic work on Semax concerns brain-derived neurotrophic factor — a protein involved in the survival, growth and maintenance of neurons — and related neuromodulatory signaling. Animal and laboratory studies have looked at how the peptide influences BDNF expression, and that is the finding usually cited.
A pathway is not a result. Saying a compound is studied around BDNF expression describes what researchers measured in a model; it says nothing about how any particular person will feel, think or perform. We are not going to bridge that gap with adjectives, and any page that does should be read with suspicion.
So this page makes no claim about memory, concentration or mental performance. What it can say honestly is that the mechanism is interesting enough to have kept researchers on it for decades.
Semax was developed at a Russian research institute and the bulk of its clinical literature was produced and published in Russia, in Russian. It is registered there as a medication and has been used clinically for years in that context.
Those studies exist, and some are human trials. They are also, for the most part, small, difficult to appraise from outside, and rarely replicated under contemporary Western trial standards. That combination — a long clinical history in one country and a thin independently auditable record elsewhere — is exactly why a compound like this belongs behind a clinician rather than in front of a page anyone can act on.
Every treatment on Promise needs the same three things before it goes live: a pharmacy willing to compound that exact preparation, an intake questionnaire written specifically for it, and a provider network prepared to prescribe it. The combination has all three. Standalone Semax has none, because it is a different formulation answering a different clinical question.
We are not taking requests for it and we will not name a date we cannot keep. The waitlist does one job — it tells us whether enough people want Semax separately to justify building the formulation, the questionnaire and the review process behind it.
If the standalone were offered, the first question a clinician would ask is why you want Semax without Selank beside it. The pair was put together to work along two axes at once, and separating them narrows the intent deliberately. That reason is worth understanding before anything is prescribed.
A licensed provider would then review the rest of it: your medications, your neurological and psychiatric history, and what you are actually trying to address. They prescribe only when a treatment is appropriate, and declining is a normal and expected outcome. Until any of that is possible, the accurate description of standalone Semax is simple — it is on the list, not on the shelf.
Semax is a synthetic peptide built from a short fragment of ACTH — adrenocorticotropic hormone — with a small tail added to the chain so that enzymes break it down more slowly. The fragment it derives from does not carry the parent hormone's cortisol-releasing activity. Research interest centers on brain-derived neurotrophic factor expression and on neuromodulatory signaling. It was developed in Russia and is not available on its own through Promise.
The formulation we currently offer puts both peptides in one vial, and the published intake questionnaire was written for that pair. [Semax / Selank](/products/semax-selank) is prescribed as a single preparation. A standalone Semax would be a different compounded product with a different clinical question behind it, and it would need its own intake before any provider could review a request for it.
We have no committed date and we are not taking requests for it. Anything that goes live here needs three things first: a pharmacy that will compound it, a clinical intake written specifically for it, and a provider network willing to prescribe it. Standalone Semax has none of those yet. The waitlist is how we judge whether the demand justifies building them.
No. Semax is not FDA-approved. It would be prepared as a compounded medication, and compounded medications are not reviewed by the FDA for safety, effectiveness, or quality. Semax has never been through a U.S. approval process; it is registered in Russia, where it was developed and where most of its clinical literature was published.
Yes. Everything Promise offers is prescription-only. You would complete an intake questionnaire written for the compound, and a licensed provider would review your health history, current medications, and neurological or psychiatric history before deciding. They prescribe only when treatment is appropriate for you.
Other Brain Health & Memory options a provider may consider.
Brain Health & Memory
Two Russian-developed peptides prescribed together: Semax, an ACTH fragment studied around BDNF expression, and Selank, a tuftsin analog studied around anxiolytic signaling.
Requires an online medical evaluation. Prescribed only when a licensed provider determines it's appropriate.